Due to the upstream role of epigenetic alterations in breast cancer phenotypes, we attempted to establish a method for tumor burden assessment by monitoring the DNMT1 activity levels in plasma samples from patients with different stages of breast cancer. Here, DNMT1 is linked to neoplasm.